Eylea® Injection for Wet Age-Related Macular Degeneration

This medicine is an intravitreal treatment used for certain retinal diseases. It can help reduce fluid and leakage under the retina and preserve central vision. This page summarizes key uses, dosing basics, and access options with US delivery from Canada. It also explains choices for paying without insurance.

What Eylea Is and How It Works

Eylea® is aflibercept, a vascular endothelial growth factor (VEGF) inhibitor for use inside the eye. It binds VEGF-A and placental growth factor, which can reduce abnormal blood vessel growth and leakage in the macula. As an Aflibercept injection, it is given by an eye specialist under sterile conditions in a clinic or surgical center. Treatment goals are to stabilize vision and decrease retinal swelling in conditions such as Wet Age Related Macular Degeneration.

Border Free Health connects U.S. patients with licensed Canadian partner pharmacies; prescriptions are verified with prescribers before dispensing.

The treatment is not self-administered. An ophthalmologist evaluates the eye, applies local anesthesia, and delivers a small-volume dose into the vitreous cavity. Appointments often include vision checks and retinal imaging to guide the plan.

Who It’s For

This therapy is approved for adults with neovascular (wet) age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and macular edema following retinal vein occlusion. Many patients begin therapy after new fluid is seen on optical coherence tomography. Those with active eye infections, significant intraocular inflammation, or known hypersensitivity to any component should not receive it. Your prescriber will evaluate one or both eyes and tailor the schedule based on response.

People living with diabetes-related swelling may find this class helps reduce central retinal thickness. Learn more about this condition on our Diabetic Macular Edema page.

Dosage and Usage

The label describes an initial series of monthly clinic injections followed by longer intervals, depending on indication and individual eye findings. After the loading phase, many patients continue every 8 weeks, with some plans extending further if the retina remains dry. Discuss the approach with a retina specialist and follow the official prescribing information for details.

An Eylea injection visit usually includes eye prep with antiseptic, a numbing drop or injection, the intravitreal dose, and short observation. Patients typically avoid rubbing the eye after the visit and report any unusual symptoms promptly. The care team monitors eye pressure and checks for signs of inflammation or infection.

Strengths and Forms

This product is supplied as single-use presentations for intravitreal use. Availability may vary by pharmacy partner and jurisdiction.

• Common presentations: 2 mg and 8 mg single-dose units
• Forms: single-dose vial or prefilled syringe, clinic-administered
• Packaging differences exist between markets; follow the label and clinic protocols

Aflibercept 8 mg offers a higher-dose option for select patients when prescribed. Final selection depends on indication, eye status, and the prescriber’s judgment.

Missed Dose and Timing

If an appointment is missed, the clinic will reschedule the next visit to maintain continuity. The treatment plan may be adjusted based on current imaging and vision findings. Do not attempt home administration; only trained eye-care professionals should perform intravitreal procedures.

Storage and Travel Basics

Pharmacy stock is typically refrigerated in the original carton and protected from light until dispensed to a clinic. Do not freeze. If you are transporting your order to a scheduled appointment, keep it in the original packaging, maintain recommended temperature, and avoid shaking. When traveling, carry documentation and keep the carton in a protected, insulated container. Clinics will store and prepare doses per the official label. We use temperature-controlled handling when required.

Single-use units are discarded after the dose. Clinics follow aseptic technique, including sterile equipment and site preparation. For broader eye-care topics and supportive therapies, you can also review our Ophthalmology category.

Benefits

As a targeted anti-VEGF therapy, this medicine can reduce fluid in and under the macula. Many patients maintain or improve central vision compared with observation alone. Clinic dosing allows close monitoring with imaging and pressure checks. Longer intervals may be possible once the retina is stable, reducing clinic visits over time.

Some patients prefer the prefilled option for streamlined clinic preparation. Others use a vial based on clinic workflow. The approach depends on prescriber preference, indication, and treatment response. For the class overall, consistent follow-up is key to protecting vision.

Some retina practices coordinate visits with imaging on the same day to simplify care. An Eylea ophthalmic injection is one option in a broader anti-VEGF toolkit that includes alternative agents for specific clinical needs.

Side Effects and Safety

• Common effects: eye pain or discomfort, conjunctival redness or hemorrhage
• Transient rise in intraocular pressure
• Floaters or visual disturbance
• Inflammation or irritation at the injection site

Serious but less common risks include endophthalmitis, retinal detachment or tear, and arterial thromboembolic events. Any intravitreal procedure, including Aflibercept injection, carries infection and pressure risks. Patients with glaucoma or on ocular hypotensive therapy may need closer pressure monitoring. Tell the clinic if there is recent stroke, severe hypertension, or pregnancy; the prescriber will weigh risks and benefits.

Drug Interactions and Cautions

Systemic interactions are limited due to local administration, but caution is advised in people with significant cardiovascular history. The medicine should not be used when there is active ocular infection or marked inflammation. Use with other intravitreal anti-VEGF agents at the same time is generally not recommended. Contact lenses are typically removed before the procedure and reinserted later per clinic guidance.

What to Expect Over Time

During the first months, many patients follow a loading schedule with frequent visits. As swelling improves, intervals may lengthen. Vision changes vary; some patients notice clearer central vision, while others primarily stabilize. Regular imaging helps guide timing. Staying on the plan, keeping appointments, and reporting changes early can support outcomes.

Compare With Alternatives

Retina specialists may consider other anti-VEGF medicines if response is suboptimal or if the regimen needs adjustment. Two approved alternatives include ranibizumab and brolucizumab. Compare profiles with your prescriber and discuss clinic workflows using these options:

• Lucentis® Vial for an alternative anti-VEGF option
• Beovu® Syringe when a different dosing approach is considered

Condition-specific pages such as Macular Edema From Retinal Vein Occlusion can also help frame questions for a retina visit.

Pricing and Access

We offer Canadian pharmacy pricing with transparent options for self-pay orders. Check the current Aflibercept price and review availability before placing an order. Our team supports US shipping from Canada with prescription validation. If you seek coupons, see our current Promotions. Final costs depend on presentation and fulfillment details set by our partner pharmacy.

Remember that clinics may have separate administration fees. Some patients coordinate purchases with upcoming visits to streamline receipt and clinic handling. Always ensure the clinic agrees to receive and administer the product you order.

Availability and Substitutions

Supply can vary by dose form, presentation, and market. If a particular presentation is unavailable, a prescriber may recommend an alternative anti-VEGF product or adjust the plan temporarily. Clinic policies differ on which units they accept, so confirm before ordering. Drug substitutions are made only with prescriber approval.

Patient Suitability and Cost-Saving Tips

Good candidates are adults with qualifying retinal conditions and no active ocular infection. Those with a history of stroke or severe cardiovascular disease require careful risk assessment by the prescriber. Consistency matters; regular visits allow imaging-guided adjustments that may extend intervals. For budgeting, consider multi-visit planning and discuss whether your clinic can coordinate a multi-month supply schedule. Refill reminders and aligning orders with appointments can help reduce missed visits and urgent rescheduling.

To learn more about related eye therapies and how they fit into care, browse articles like Combigan Eye Drops and Azopt Eye Drops.

Questions to Ask Your Clinician

• Diagnosis details: what imaging shows and how fluid is changing
• Planned interval: loading phase, extension criteria, and monitoring
• Clinic workflow: vial versus prefilled syringe preferences
• Safety checks: pressure monitoring and signs of infection
• Alternative options: when to consider switching agents
• Travel planning: handling, timing, and appointment coordination

Authoritative Sources

Manufacturer Product Page

FDA DailyMed

Health Canada Drug Product Database

Ready to proceed? You can place an order today for clinic use with prompt, express shipping that ships from Canada to US. This information is educational and does not replace your prescriber’s advice or the official label.